Vertex has secured exclusive options to license Skyhawk Therapeutics’ candidates that modulate RNA splicing. The deal will see Vertex pay Skyhawk $40 million upfront and commit to up to $2.2 billion ...
Skyhawk and Merck KGaA collaborate to discover RNA-targeting small molecules for neurological disorders using Skyhawk's SkySTAR platform. Skyhawk will focus on discovery and preclinical development, ...
Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Under the agreement, Skyhawk will use its RNA splicing platform, dubbed ...
BOSTON, July 10, 2024 (GLOBE NEWSWIRE) -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback